Jan E. Eickhoff

Dortmund, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Inhibition of RNA polymerase II-activating CDK9 and CDK12/13, but not of cell cycle relevant CDKs, induces apoptosis by downregulating the short-lived Bcl-2 proteins Mcl1 and Bfl1/A1.

Inhibition of RNA polymerase II-activating CDK9 and CDK12/13, but not of cell cycle relevant CDKs, induces apoptosis by downregulating the short-lived Bcl-2 proteins Mcl1 and Bfl1/A1.

Journal: Cell death & disease

Published: January 09, 2026

Evaluating Triazole-Substituted Pyrrolopyrimidines as CSF1R Inhibitors.

Evaluating Triazole-Substituted Pyrrolopyrimidines as CSF1R Inhibitors.

Journal: Molecules (Basel, Switzerland)

Published: May 26, 2025

Design and Synthesis of Pyridine-Based Pyrrolo[2,3-d]pyrimidine Analogs as CSF1R Inhibitors: Molecular Hybridization and Scaffold Hopping Approach.

Design and Synthesis of Pyridine-Based Pyrrolo[2,3-d]pyrimidine Analogs as CSF1R Inhibitors: Molecular Hybridization and Scaffold Hopping Approach.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: April 29, 2025

Fragment-Based Interrogation of the 14-3-3/TAZ Protein-Protein Interaction.

Fragment-Based Interrogation of the 14-3-3/TAZ Protein-Protein Interaction.

Journal: Biochemistry

Published: August 22, 2024

Development of a live cell assay for real-time monitoring the interactions between the Hippo pathway components 14-3-3 and TAZ.

Development of a live cell assay for real-time monitoring the interactions between the Hippo pathway components 14-3-3 and TAZ.

Journal: SLAS discovery : advancing life sciences R & D

Published: May 15, 2024

An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity.

An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity.

Journal: Pharmaceutics

Published: December 19, 2023

Pyrrolopyrimidine based CSF1R inhibitors: Attempted departure from Flatland.

Pyrrolopyrimidine based CSF1R inhibitors: Attempted departure from Flatland.

Journal: European journal of medicinal chemistry

Published: November 09, 2023

Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers.

Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers.

Journal: Pharmaceutics

Published: October 25, 2023

Cytomegalovirus cyclin-dependent kinase ortholog vCDK/pUL97 undergoes regulatory interaction with human cyclin H and CDK7 to codetermine viral replication efficiency.

Cytomegalovirus cyclin-dependent kinase ortholog vCDK/pUL97 undergoes regulatory interaction with human cyclin H and CDK7 to codetermine viral replication efficiency.

Journal: Virus research

Published: June 15, 2023

Characterization of the Antibacterial Activity of Quinone-Based Compounds Originating from the Alnumycin Biosynthetic Gene Cluster of a Streptomyces Isolate.

Characterization of the Antibacterial Activity of Quinone-Based Compounds Originating from the Alnumycin Biosynthetic Gene Cluster of a Streptomyces Isolate.

Journal: Antibiotics (Basel, Switzerland)

Published: May 25, 2023

Synthesis and Development of Highly Selective Pyrrolo[2,3-d]pyrimidine CSF1R Inhibitors Targeting the Autoinhibited Form.

Synthesis and Development of Highly Selective Pyrrolo[2,3-d]pyrimidine CSF1R Inhibitors Targeting the Autoinhibited Form.

Journal: Journal of medicinal chemistry

Published: May 16, 2023

Assessment of Covalently Binding Warhead Compounds in the Validation of the Cytomegalovirus Nuclear Egress Complex as an Antiviral Target.

Assessment of Covalently Binding Warhead Compounds in the Validation of the Cytomegalovirus Nuclear Egress Complex as an Antiviral Target.

Journal: Cells

Published: January 27, 2023

Showing 1-12 of 31

Last Updated: 09/26/2026